Science magazine describes international WHO clinical trial for covid-19. It randomizes between local standard of care, Remdisivir, HCQ/CQ, Kaletra, or Kaletra plus interferon beta. No placebo and the only endpoints they measure are time in hospital, whether patient needed oxygen or ventilator, and death which makes it easy to run compared to placebo controlled trial. It is not clear to me in article which patients are eligible — it seems to be all hospitalized patients. Promises to be very large study with thousands of participants. Not sure what to make of limiting to these endpoints given all but death will depend on local hospital practices.